BVF Inc. IL Acquires 1,438,760 Shares of Xencor, Inc. (NASDAQ:XNCR)

BVF Inc. IL grew its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 169.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,288,760 shares of the biopharmaceutical company's stock after acquiring an additional 1,438,760 shares during the period. Xencor accounts for about 1.8% of BVF Inc. IL's investment portfolio, making the stock its 14th biggest position. BVF Inc. IL owned approximately 3.27% of Xencor worth $52,596,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of XNCR. Vanguard Group Inc. raised its position in Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company's stock worth $184,239,000 after purchasing an additional 418,040 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Xencor by 2.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company's stock worth $92,758,000 after acquiring an additional 107,350 shares during the last quarter. TCG Crossover Management LLC lifted its stake in shares of Xencor by 1.0% during the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC boosted its holdings in Xencor by 12.3% in the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company's stock valued at $37,578,000 after acquiring an additional 179,526 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Xencor by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company's stock worth $34,509,000 after purchasing an additional 102,297 shares during the period.

Xencor Trading Down 5.6 %

Shares of NASDAQ XNCR traded down $0.47 during midday trading on Wednesday, reaching $7.99. 1,982,935 shares of the stock were exchanged, compared to its average volume of 636,181. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 12 month low of $7.16 and a 12 month high of $27.24. The business has a 50-day simple moving average of $11.11 and a two-hundred day simple moving average of $17.90. The company has a market capitalization of $568.50 million, a price-to-earnings ratio of -2.50 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. During the same period in the prior year, the business earned ($1.11) EPS. The firm's revenue was up 104.6% on a year-over-year basis. As a group, equities research analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on XNCR shares. William Blair assumed coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wedbush reaffirmed an "outperform" rating and set a $31.00 target price on shares of Xencor in a report on Wednesday, April 30th. Finally, Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $32.86.

Insider Activity at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This represents a 8.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.23% of the stock is owned by insiders.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.